ROR1-based immunomagnetic protocol allows efficient separation of CLL and healthy B cells
| Authors | |
|---|---|
| Year of publication | 2016 |
| Type | Article in Periodical |
| Magazine / Source | British Journal of Haematology |
| MU Faculty or unit | |
| Citation | |
| Web | http://onlinelibrary.wiley.com/doi/10.1111/bjh.13848/epdf |
| Doi | http://dx.doi.org/10.1111/bjh.13848 |
| Field | Oncology and hematology |
| Keywords | ROR1; cell isolation; chronic lymphocytic leukaemia; complete remission |
| Attached files | |
| Description | Chronic lymphocytic leukaemia (CLL) is the most common leukaemia among adults in the Western world. This lymphoproliferative disorder is defined by the presence of at least 5 9 106 clonal lymphocytes/ml peripheral blood (Hallek,2015). The biggest clinical challenge is the fact that CLL eradication by any available therapy, apart from allogeneic stem cell transplantation, fails to cure the disease, inducing only temporary disease remission, i.e., when the disease does not manifest clinically but CLL cells still persist in the body. During this phase a population of CLL cells often slowly re-expands to trigger CLL relapse. The relapse is often based on the poorly understood but clinically important process of therapy-driven selection of more aggressive CLL subclones (Malcikova et al, 2015). |
| Related projects: |